Company intelligence / Profile preview

Hutchison Whampoa Guangzhou Baiyunshan

Guangzhou, Guangdong, Chinabyszc.com ↗

Ownership: Private
Employees: ~1300
Development stage: Other

Overview

Guangzhou Baiyunshan Pharmaceutical is one of China's largest pharmaceutical companies, engaged in R&D, manufacturing, and sales of Chinese and Western medicines. It has a broad commercial portfolio with over 300 products across multiple therapeutic areas. The company has developed both generic and innovative drugs, such as generic sildenafil citrate ("JinGe") and novel cephalosporins. Recent clinical studies include combination therapies for chronic periodontitis.

Therapeutic areas: Infectious DiseasesMen's HealthNeurologyOncology
Modalities: Small moleculeBiologic
Industry: Pharma

Beyond the preview

Go deeper on Hutchison Whampoa Guangzhou Baiyunshan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hutchison Whampoa Guangzhou Baiyunshan.